Article

Prospective evaluation of risk factors for male breast cancer.

Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852-7234, USA.
CancerSpectrum Knowledge Environment (Impact Factor: 15.16). 10/2008; 100(20):1477-81. DOI: 10.1093/jnci/djn329
Source: PubMed

ABSTRACT Most risk factors for male breast cancer have been derived from retrospective studies that may reflect selective recall. In the prospective National Institutes of Health-AARP Diet and Health Study, we studied 324 920 men, among whom 121 developed breast cancer. Men who reported a first-degree relative with breast cancer had an increased risk of breast cancer (relative risk [RR] = 1.92, 95% confidence interval [CI] = 1.19 to 3.09). Among the medical conditions examined, a new finding emerged regarding increased male breast cancer risk associated with a history of a bone fracture (RR = 2.20, 95% CI = 1.24 to 3.91). Obesity was positively related to risk (RR = 1.79, 95% CI = 1.10 to 2.91, for body mass indices of >or=30 vs <25 kg/m2) and physical activity inversely related, even after adjustment for body mass index. Smokers were at somewhat elevated risk, although trends with smoking characteristics were inconsistent. Alcohol consumption was not related to risk. The identified risk factors show some commonalities with female breast cancer and indicate the importance of hormonal mechanisms. Differences in risk factors may reflect unique mechanisms associated with androgens and their ratio to bioavailable estrogens.

0 Followers
 · 
92 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ARTICLE INFO ABSTRACT Background for about 1% of all the malignancies in men as well as for 1% of all of breast carcinoma. Nearly all of the men with breast cancer do not have any distinguishable risk fact breast cancer presents at older ages as opposed to females with breast cancer. Case presentation 2014. azoospermic MBC patients additional biochemical markers were done (Total testosterone, Follic stimulating hormone and total cholesterol) before starting treatment. Results MBC patients insignificantly in MBC patients. Conclusion chance to develop breast cancer by a mutual mechanism which affects the function of androgen receptors.
    International Journal of Current Research 02/2015; 7(2):12642-12644.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Male breast cancer is an uncommon malignancy; little is known regarding hormonal manipulations for tamoxifen-resistant male breast cancer patients. This is the first pooled analysis of the literature to synthesize all available data and to evaluate the efficacy and safety of fulvestrant in male breast cancer. This study was performed in accordance with the PRISMA guidelines. All studies that examined the efficacy of fulvestrant in male breast cancer, regardless of sample size, were considered eligible. The search strategy retrieved 31 articles; of these, five articles were eligible (23 patients) for this pooled analysis. The mean age of the study sample was 63.1 years. Adjuvant hormonal treatment was administered in 87.5 % of cases. Fulvestrant was given as first or second line in 40 % of patients, while as third line or beyond in 60 % of patients. 79.0 % of patients at fulvestrant administration had visceral metastases. Regarding best response, in 26.1 % PR was achieved, in 47.8 % of cases SD was recorded, whereas in 26.1 % of patients PD was noted. The median PFS was equal to 5 months. No grade 3 and 4 adverse events were recorded; of note, hot flashes were reported in 18.2 % of male breast cancer patients. Fulvestrant may potentially play a promising role in the optimal therapeutic strategy for male patients with breast cancer diagnosis. However, further clinical and pharmacokinetic investigations are more than warranted before fulvestrant use becomes a common practice in male breast cancer patients.
    Breast Cancer Research and Treatment 12/2014; 149(1). DOI:10.1007/s10549-014-3240-z · 4.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ARTICLE INFO ABSTRACT Background for about 1% of all the malignancies in men as well as for 1% of all of breast carcinoma. Nearly all of the men with breast cancer do not have any distinguishable risk fact breast cancer presents at older ages as opposed to females with breast cancer. Case presentation 2014. azoospermic MBC patients additional biochemical markers were done (Total testosterone, Follic stimulating hormone and total cholesterol) before starting treatment. Results MBC patients insignificantly in MBC patients. Conclusion chance to develop breast cancer by a mutual mechanism which affects the function of androgen receptors.

Preview

Download
3 Downloads
Available from